Launch week offerEnds in00h00m00s

Thomas Proft

Has grant

Professor

University of Auckland
Country flagNew Zealand

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Professor Thomas Proft is a faculty member at The University of Auckland in New Zealand. His research focuses on the pathogenesis of Group A Streptococcus, including its virulence factors and implications for vaccine development. Recent publications highlight his work on the immune evasion strategies of pathogenic Gram-positive bacteria and novel mechanisms to enhance oral drug delivery through PEGylated niosomes.

Recent Grants

Grant: Open

Complement evasion factor (CEF) - a novel candidate for the development of a vaccine against Group A Streptococcus.

Open Date: 2024-01-01

Close Date: 2027-01-01

Grant: Close

Investigations into a novel putative immune evasion factor from Group A Streptococcus

Open Date: 2018-11-01

Close Date: 2020-11-01

Grant: Close

GASPEL - a novel mucosal vaccine against Group A Streptococcus?

Open Date: 2018-10-01

Close Date: 2020-09-01

Grant: Close

PilVax a novel peptide delivery strategy for the development of vaccines against TB

Open Date: 2017-03-01

Close Date: 2020-02-01

Grant: Close

PilVax: a novel peptide delivery strategy for the development of vaccines

Open Date: 2017-01-01

Close Date: 2020-01-01

Articles (16)

Year:

2026

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

The human pathogen Streptococcus pyogenes , or Group A Streptococcus (GAS), is associated with a variety of diseases ranging from mild skin and soft tissue infections to invasive diseases and immune sequelae such as rheumatic heart disease. We have recently reported that one of the virulence factors of this pathogen, the pilus, has inflammatory properties and strongly stimulates the innate immune system. Here we used a range of nonpathogenic Lactococcus lactis gain‐of‐function mutants, each expressing one of the major pilus types of GAS, to compare the immune responses generated by various types of fully assembled pili. In vitro assays indicated variability in the inflammatory response induced by different pili, with the fibronectin‐binding, collagen‐binding, T antigen (FCT)‐1‐type pilus from GAS serotype M6/T6 inducing significantly stronger cytokine secretion than other pili. Furthermore, we established that the same trend of pili‐mediated immune response could be modeled in Galleria mellonella larvae, which possess a similar innate immune system to vertebrates. Counterintuitively, across the panel of pili types examined in this study, we observed a negative correlation between the intensity of the immune response demonstrated in our experiments and the disease severity observed clinically in the GAS strains associated with each pilus type. This observation suggests that pili‐mediated inflammation is more likely to promote bacterial clearance instead of causing disruptive damages that intensify pathogenesis. This also indicates that pili may not be the main contributor to the inflammatory symptoms seen in GAS diseases. Rather, the immune‐potentiating properties of the pilus components could potentially be exploited as a vaccine adjuvant.

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Joanna Kirman

Associate Professor

University of Otago

NEW ZEALAND
View details

Jacelyn Mei San Loh

-

NEW ZEALAND
View details

Yi Tian Ting

MONASH UNIVERSITY

AUSTRALIA
View details

Adrina Hema Jethanand-Khemlani

University of Auckland

NEW ZEALAND
View details

Darren Svirskis

University of Auckland

NEW ZEALAND
View details

Catherine Jia‐Yun Tsai

Senior Research Fellow

University of Auckland

NEW ZEALAND
View details

Mengyang Liu

University of Auckland

NEW ZEALAND
View details

Julie Bennett

Associate Professor

University of Otago

NEW ZEALAND
View details

Jingyuan Wen

Professor

University of Auckland

NEW ZEALAND
View details